-
31.发明授权公开(公告)号：US10214585B2
公开(公告)日：2019-02-26
申请号：US14850794
申请日：2015-09-10
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K38/00 , A61K31/4155 , A61K38/16 , A61K38/18 , A61K38/20 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/02 , A61K39/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
32.发明授权公开(公告)号：US09982047B2
公开(公告)日：2018-05-29
申请号：US15821570
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K38/20 , A61K33/36 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K38/16 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
33.发明授权Reducing systemic regulatory T cell levels or activity for treatment of Alzheimer's disease 有权减少系统性调节性T细胞水平或治疗阿尔茨海默病的活性公开(公告)号：US09534052B2
公开(公告)日：2017-01-03
申请号：US15212231
申请日：2016-07-16
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K38/00 , A61K31/4155 , A61K39/395 , A61K38/16 , A61K38/18 , A61K38/20 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。
-
公开(公告)号：US09517256B2
公开(公告)日：2016-12-13
申请号：US14162482
申请日：2014-01-23
Applicant: Yeda Research and Development Co., Ltd.
Inventor： Michal Eisenbach-Schwartz , Ester Yoles , Oleg Butovsky , Jonathan Kipnis
IPC: A61K39/00
CPC classification number: A61K39/0007 , A61K39/00 , A61K39/0008 , A61K2039/5158
Abstract: Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii).
Abstract translation: 提供方法和组合物用于治疗除了朊病毒疾病之外存在错误折叠和/或聚集蛋白质积累的神经变性疾病。 特别地，本发明涉及治疗神经退行性疾病亨廷顿病（HD），阿尔茨海默病（AD）或帕金森病（PD）），通过施用选自（i）共聚物1，（ii） 共聚物1相关肽，（iii）共聚物1相关多肽，和（iv）用（i），（ii）或（iii）活化的T细胞。
-
35.发明申请公开(公告)号：US20160297880A1
公开(公告)日：2016-10-13
申请号：US15190160
申请日：2016-06-22
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K31/4155
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
Patent Agency Ranking
36.发明申请CELLULAR MARKERS FOR DIAGNOSIS OF ALZHEIMER'S DISEASE AND FOR ALZHEIMER'S DISEASE PROGRESSION 审中-公开用于诊断阿尔茨海默病和阿尔茨海默氏病进展的细胞标志物公开(公告)号：US20150057176A1
公开(公告)日：2015-02-26
申请号：US14388369
申请日：2013-03-21
Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD. , NEUROQUEST LTD.
Inventor： Michal Eisenbach-Schwartz , Ester Yoles
IPC: G01N33/569 , G01N33/50
CPC classification number: G01N33/56972 , G01N33/5047 , G01N33/505 , G01N2800/2821 , G01N2800/50 , G01N2800/52
Abstract: The present invention provides methods for early diagnosis of Alzheimer's disease and for determining the efficacy of a treatment for Alzheimer's disease in an Alzheimer's patient, i.e., monitoring Alzheimer's disease progression, utilizing cellular blood markers; as well as kits for carrying out these methods.
Abstract translation: 本发明提供早期诊断阿尔茨海默氏病和确定阿尔茨海默病患者阿尔茨海默病治疗功效的方法，即利用细胞血标记物监测阿尔茨海默病进展; 以及执行这些方法的工具包。
-
公开(公告)号：US20150051151A1
公开(公告)日：2015-02-19
申请号：US14384685
申请日：2013-03-14
Inventor： Michal Eisenbach-Schwartz , Matityahu Fridkin , Michal Cardon-Yaakov
CPC classification number: C07K7/06 , A61K9/0053 , A61K38/00 , C07K7/64
Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
Abstract translation: 本申请提供五至七个天然或非天然氨基酸的合成修饰肽以及包含它们的药物组合物，用于治疗与感觉门控功能障碍，抑郁症或认知障碍相关的行为异常的疾病或病症 ，特别是精神分裂症和阿尔茨海默病。
-
38.发明授权公开(公告)号：US11732046B2
公开(公告)日：2023-08-22
申请号：US17222370
申请日：2021-04-05
Inventor： Ester Yoles , Berit Olsen Krogh , Allan Jensen , Jan Egebjerg , Carol David , Kuti Baruch , Michal Eisenbach-Schwartz
CPC classification number: C07K16/2827 , A61K2039/505 , C07K2317/515 , C07K2317/56
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
-
39.发明授权公开(公告)号：US11492405B2
公开(公告)日：2022-11-08
申请号：US16728642
申请日：2019-12-27
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61P25/16 , A61P25/28 , A61K31/4155 , A61K31/7068 , A61K31/404 , A61K33/36 , A61K45/06 , A61P37/06 , A61P27/02 , A61K39/00
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
40.发明申请公开(公告)号：US20210221888A1
公开(公告)日：2021-07-22
申请号：US17186960
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K39/395 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
-
-
-
-
-
-
-
-
Search Results
52
records
(took 0.03 seconds)
